Susquehanna International Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-89,400
| Closed | -$4.24M | – | 12228 |
|
|
2025
Q3 | $4.24M | Sell |
89,400
-235,800
| -73% | -$11.4M | ﹤0.01% | 4354 |
|
|
2025
Q2 | $17.4M | Buy |
325,200
+226,000
| +228% | +$10.3M | ﹤0.01% | 2157 |
|
|
2025
Q1 | $4.02M | Buy |
99,200
+36,000
| +57% | +$1.53M | ﹤0.01% | 4070 |
|
|
2024
Q4 | $1.76M | Sell |
63,200
-24,700
| -28% | -$748K | ﹤0.01% | 5599 |
|
|
2024
Q3 | $2.52M | Buy |
87,900
+4,800
| +6% | +$125K | ﹤0.01% | 4842 |
|
|
2024
Q2 | $1.95M | Sell |
83,100
-87,500
| -51% | -$1.87M | ﹤0.01% | 5150 |
|
|
2024
Q1 | $4.31M | Buy |
170,600
+67,300
| +65% | +$1.62M | ﹤0.01% | 3882 |
|
|
2023
Q4 | $2.41M | Sell |
103,300
-1,037,200
| -91% | -$20.5M | ﹤0.01% | 4975 |
|
|
2023
Q3 | $57.7M | Buy |
1,140,500
+688,600
| +152% | +$32.1M | 0.01% | 917 |
|
|
2023
Q2 | $21.1M | Buy |
451,900
+310,300
| +219% | +$14.2M | ﹤0.01% | 1670 |
|
|
2023
Q1 | $5.42M | Sell |
141,600
-8,500
| -6% | -$379K | ﹤0.01% | 3350 |
|
|
2022
Q4 | $8.23M | Sell |
150,100
-194,700
| -56% | -$8.34M | ﹤0.01% | 2526 |
|
|
2022
Q3 | $11.7M | Buy |
+344,800
| New | +$5.28M | ﹤0.01% | 1959 |
|
|
2022
Q1 | – | Sell |
-15,600
| Closed | -$330K | – | 12902 |
|
|
2021
Q4 | $330K | Sell |
15,600
-18,400
| -54% | -$408K | ﹤0.01% | 10242 |
|
|
2021
Q3 | $760K | Sell |
34,000
-78,500
| -70% | -$1.78M | ﹤0.01% | 8270 |
|
|
2021
Q2 | $2.79M | Sell |
112,500
-394,000
| -78% | -$11.1M | ﹤0.01% | 5188 |
|
|
2021
Q1 | $14.7M | Buy |
506,500
+470,600
| +1,311% | +$14.2M | ﹤0.01% | 2264 |
|
|
2020
Q4 | $926K | Buy |
35,900
+800
| +2% | +$22.3K | ﹤0.01% | 6894 |
|
|
2020
Q3 | $1.08M | Buy |
35,100
+24,700
| +238% | +$863K | ﹤0.01% | 5919 |
|
|
2020
Q2 | $259K | Buy |
+10,400
| New | +$238K | ﹤0.01% | 8606 |
|
Other funds holding AKRO
Susquehanna International Group's AKRO Position: Q4 2025 in Review
Susquehanna International Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 50,683 shares — an estimated $2.41M sold.
Susquehanna International Group first reported a position in AKRO in Q1 2020 and held it in 22 quarters. The position peaked at $17.7M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Susquehanna International Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Susquehanna International Group sold 50,683 Akero Therapeutics shares in Q4 2025, an estimated $2.41M.
- Susquehanna International Group first reported a position in Akero Therapeutics in Q1 2020 and held it in 22 quarters.
- Susquehanna International Group's Akero Therapeutics position peaked at $17.7M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.